An update on the malignant hyperthermia syndrome

Area of Science:

• Pharmacogenetics
• Skeletal Muscle Physiology
• Anesthesiology

Background:

• Malignant hyperthermia (MH) is a pharmacogenetic disorder of skeletal muscle, inherited differently in humans (autosomal dominant) and swine (recessive).
• Susceptibility to MH is typically asymptomatic until exposure to specific anesthetic agents like isoflurane, enflurane, or succinylcholine.
• Exposure triggers a hypermetabolic state, leading to acidosis, muscle rigidity, rhabdomyolysis, and potentially fatal hyperthermia, with mortality rates up to 70% if untreated.

Purpose of the Study:

• To explore the pathophysiology of malignant hyperthermia, focusing on calcium flux defects in skeletal muscle.
• To investigate the genetic basis of MH, particularly the role of the ryanodine receptor calcium channel.
• To highlight the need for improved diagnostic methods and a deeper understanding of MH and related myopathies.

Main Methods:

• Review of existing literature on malignant hyperthermia genetics and pathophysiology.
• Comparison of MH inheritance patterns and clinical presentations in humans and swine models.
• Analysis of the role of specific gene mutations, such as those in the ryanodine receptor, in MH susceptibility.

Main Results:

• MH pathophysiology involves a defect in skeletal muscle calcium flux.
• A specific mutation in the ryanodine receptor gene is identified in susceptible swine but is rare in humans.
• MH is more prevalent in children, who may exhibit paradoxical jaw muscle hypertonia to succinylcholine.

Conclusions:

• Prompt diagnosis and dantrolene sodium treatment significantly reduce MH mortality to less than 10%.
• Understanding the molecular genetics of MH is crucial for developing simpler diagnostic tests.
• Further research into MH genetics can enhance our understanding of this disorder and its relationship to other myopathies.